Navigation Links
MedX Health Announces Initiation of Laser Acupuncture Study for Controlling Addiction

    North American Trial will Determine Effectiveness of Laser Acupuncture
    for Reducing Addiction to Nicotine, Alcohol and Drugs

MISSISSAUGA, ON, Jan. 22 /PRNewswire-FirstCall/ - MedX Health Corp., (TSXV.MDX) a global leader in developing drug free, non-invasive low level laser and light therapy for tissue repair and pain relief, today announced that the company has received FDA Institutional Review Board (IRB) approval to study the effectiveness of laser acupuncture for addiction to nicotine, alcohol and drugs. This study, to be launched in both Canada and the United States, will be an open, multi-center trial treating patients with addictions to assess the effectiveness of using the MedX laser probe as a means of controlling the need for these substances.

The most common addictions are to legal substances, including nicotine, alcohol and drugs such as prescription painkillers. Each can lead to a number of debilitating conditions and even death.

"While the use of laser therapy in addiction is not a new concept, it has not been well-documented and it is important that MedX conduct these meaningful studies to confirm the efficacy of our laser and established treatment protocols for these addictions. This would lead to a more cost-effective way to treat addiction," states Steve Guillen, president and CEO of MedX Health. "This is just the beginning of a number of trials we plan to launch in laser acupuncture with our MedX laser probe. Our goal is to institute a safe and effective standard of care for those suffering from substance abuse and the serious medical conditions that can result from drug, alcohol, and smoking addictions," adds Guillen.

"Each clinic that participates in the study will use our MedX laser probe with established protocols and will be responsible for documenting and sending us data regularly, which will be analyzed and published on a yearly basis," explains Anita Saltmarche, RN, MHSc, vice president of clinical and scientific affairs.

About the trial

The MedX multi-center trial will determine the effectiveness of laser acupuncture for treating a number of major health conditions that significantly contribute to morbidity and mortality. Drug, alcohol, and smoking addictions cost individuals, society and the health care system millions in treating these addictions, including various cessation programs.

MedX will be working with sites across the US and Canada to enroll patients interested in participating in studies using low level laser therapy for auricular acupuncture for smoking, drug or alcohol abuse.

The comprehensive addiction treatment program and study includes well-established staff education and training, marketing materials and innovative low level laser technology to ensure a high quality, standardized treatment protocol. The research results will assist in guiding clinical practice and increasing the likelihood of successful outcomes for patients experiencing an array of significant health issues.

About Laser Auriculotherapy

Laser Auriculotherapy is the stimulation of points on the external ear and in some cases meridian points in other parts of the body, to aid many health conditions, especially pain, stress and addiction. Based on years of experience experts believe that this stimulation will lead to a reduction in the patient's need for the substances. The reduced cravings outcome with laser auricular acupuncture is based on the recent observation that the ear represents a door into the endocrine and autonomic nervous systems. In 1997, a consensus panel of the US National Institutes of Health gave approval to the practice of acupuncture, which included an evaluation of those studies which supported the use of ear acupuncture for pain and addiction.

About Tobacco, Alcohol and Drug Addiction

According to the Centers for Disease Control, tobacco use remains the leading preventable cause of disease and deaths in the US, causing approximately 440,000 premature deaths each year resulting in 13.2 years of potential life lost for male smokers, and 14.5 years lost for female smokers. This is associated with an estimated $192 billion in annual medical expenditures and lost productivity.

A study published in the Journal of the American Medical Association in 2004 found that excessive alcohol consumption is the third leading preventable cause of death in the United States and is associated with multiple adverse health consequences, including liver cirrhosis, various cancers, unintentional injuries, and violence. In 2001, an estimated 75,766 alcohol-attributable deaths (AADs) and 2.3 million years of potential life lost, or approximately 30 years of life lost on average per AAD, were attributable to excessive alcohol use in 2001.

According to the National Institutes for Drug Abuse, addiction to alcohol, nicotine, and illegal substances cost Americans upwards of half a trillion dollars a year, considering their combined medical, economic, criminal, and social impact. Every year, abuse of illicit drugs and alcohol contributes to the death of more than 100,000 Americans.

About MedX

MedX Health is a global leader in the design, manufacturing and distribution of quality low level laser and light therapy technology for use in numerous medical settings that provide patients with non-invasive, drug-free solutions for improving clinical outcomes. MedX's innovative Laser/Light Therapy devices not only enhance the rehabilitation process and clinical outcomes for people seeking relief from pain and other physical ailments, but can now help individuals to overcome addictions.

    The TSX Venture Exchange does not accept responsibility for the adequacy
    or accuracy of this press release.

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Such forward-looking information may include statements regarding the Company's future plans, objectives, performance, growth, profits, operating expenses or its underlying assumptions. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "does not anticipate", or "believes" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", or "will be taken", "occur", or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of MedX to be materially different from those expressed or implied by such forward-looking information, including uncertainty of successful development of new products, uncertainty of successful manufacturing or marketing of products, uncertainty of commercial acceptance of products, uncertainty concerning governmental regulation, dependency on key employees and relationships, rapid technological changes, foreign currency fluctuations. MedX does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

SOURCE MedX Health Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Air pollution linked to cardiovascular risk indices in healthy young adults
4. More proof needed of safety and quality of electronic personal health records
5. Health care incentive model offers collaborative approach
6. Loneliness is bad for your health
7. Mailman School of Public Health study examines link between racial discrimination and substance use
8. Green Tea May Brew Up Healthier Skin
9. For Health Info, Women Often Turn to the Web
10. Record Number of Americans Lack Health Insurance
11. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science
Post Your Comments:
(Date:12/1/2015)... Middletown, PA (PRWEB) , ... December 01, 2015 ... ... separate environments; however, there are professionals who believe that with innovative technologies and ... services allows the patient to get the benefit of a dual-approach to his ...
(Date:12/1/2015)... ... 01, 2015 , ... CloudLIMS today announced that it is ... under the New Products and Services category for its innovative product offering, BioTracer. ... that helps labs organize data and track samples with storage inventories. BioTracer's ...
(Date:12/1/2015)... ... December 01, 2015 , ... The importance of volumetric ... the focus of numerous abstracts accepted for presentation here, at the 101st Annual ... abstracts highlight the use of Volpara Solutions’ quantitative breast imaging software tools for ...
(Date:12/1/2015)... ... December 01, 2015 , ... SAN ... today announced that the organization has awarded Education and Developmental Therapies (EDT), an ... Award. The award celebrates exceptional special needs providers that excel in synthesizing the ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... the care management and population health arenas, is pleased to announce that VIP ... containment services, has successfully implemented the ACUITY Complete Care™ Management to back their ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015  Athletic apparel ... founder have agreed to pay $1.35 million to ... advertised the company,s copper-infused compression clothing would relieve ... arthritis and other diseases. Tommie ... requires the company and its founder and chairman ...
(Date:12/1/2015)... 2015 Pharma Tech Outlook recently conducted a ... Data Management Solution Providers - 2015 .  After careful ... CEOs, CIOs, VCs, analysts, and the Pharma Tech Outlook ... top 10 clinical data management solution providers (check out ... and 36 respectively). --> ...
(Date:12/1/2015)... and PITTSBURGH , Dec. ... announced that it expects to be the first to ... funded by international donors, TLE400 (Tenofovir Disoproxyl Fumarate 300 ... for $99 per patient, per year. Mylan partnered with ... The significantly reduced price could generate savings of tens ...
Breaking Medicine Technology: